Patrys Limited (ASX:PAB)

Australia flag Australia · Delayed Price · Currency is AUD
0.0350
-0.0030 (-7.89%)
Mar 4, 2026, 3:22 PM AEST
Market Cap20.34M +147.2%
Revenue (ttm)100.38K -93.1%
Net Income-4.51M
EPS-0.02
Shares Out535.37M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume461,991
Average Volume1,161,017
Open0.0360
Previous Close0.0380
Day's Range0.0350 - 0.0360
52-Week Range0.0120 - 0.0490
Beta0.74
RSI59.12
Earnings DateFeb 22, 2026

About Patrys

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is base... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 10
Stock Exchange Australian Securities Exchange
Ticker Symbol PAB
Full Company Profile

Financial Performance

In fiscal year 2025, Patrys's revenue was 828,540, a decrease of -40.57% compared to the previous year's 1.39 million. Losses were -3.01 million, -14.86% less than in 2024.

Financial Statements